Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics

PARSIPPANY, N.J., Oct. 29 /PRNewswire/ -- Ferring Pharmaceuticals Inc. announces the appointment of Harry F. Kovelman, MD as Associate Medical Director for Orthopaedics. Dr. Kovelman will be responsible for medical affairs for EUFLEXXA(R)( ) (1% sodium hyaluronate), a treatment for knee pain due to osteoarthritis, as well as Ferring's expanding line of orthopaedic products.

Dr. Kovelman joins Ferring with a broad range of experience in medical affairs, business development, sales and marketing in the medical and orthopaedic device industries. Prior to joining Ferring, Dr. Kovelman was Director of Medical Affairs at Otto Bock HealthCare, which provides equipment for restorative health. He has also served as Chief Executive Officer of Archimedes Medical Technology, a consulting services company for the medical device industry; Executive Director, Orthopaedic Institute of St. Joseph Medical Center in Maryland; and Medical Affairs Director and Vice President of Sales and Marketing at Dynasplint Systems, Inc., manufacturer of medical devices for range-of-motion loss.

About EUFLEXXA(R)( )

EUFLEXXA(R)( ) (1% sodium hyaluronate) is the first non-avian derived* hyaluronic acid (HA) approved in the U.S. for treatment of knee pain due to osteoarthritis (OA). EUFLEXXA(R) is indicated for patients who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy. The process used to manufacture EUFLEXXA(R) results in highly-purified HA with properties similar to the HA in healthy human synovial fluid.(1-4) EUFLEXXA(R) received approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004 and became available to the public on November 8, 2005. For more information, visit www.EUFLEXXA.com.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of infertility, urology, and orthopaedic products in the U.S. market. They include: BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R)( )and REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP), ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg, FIRMAGON(R)( ) (degarelix for injection), PROSED(R) DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA(R) (1% sodium hyaluronate).

*Derived through bacterial fermentation

Ferring Pharmaceuticals Inc.


Back to news